Enhancing diagnostic preparedness for H5N1: a validation study of H5 single-plex assay and detection across multiple

Yuan Chao Xue1, Jennifer Bertsch1, Kaylin Monacy1

  • 1Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.

Insights

Commercial respiratory panels can detect avian influenza (H5N1) but lack subtype identification. A new H5 assay enhances detection for better clinical and public health responses to H5N1.

Area of Science:

  • Clinical microbiology
  • Infectious disease diagnostics
  • Public health surveillance

Background:

  • Increasing transmission of highly pathogenic avian influenza (HPAI) H5N1 from animals to humans necessitates improved diagnostic tools.
  • Current commercial multiplex respiratory panels may detect H5N1 but lack specific H5N1 subtyping capabilities, with unverified real-world performance.

Purpose of the Study:

  • To evaluate the limit of detection (LoD) of three commercial molecular diagnostic assays for H5N1.
  • To develop and validate a real-time RT-PCR assay for H5 subtype detection on the Hologic Panther Fusion platform.

Main Methods:

  • Evaluation of H5N1 LoD using bioMérieux BioFire Respiratory 2.1 Panel, Cepheid Xpert Xpress CoV-2/Flu/RSV Plus, and Hologic Panther Fusion SARS-CoV-2/Flu A/B/RSV assays.
  • Development and validation of a real-time RT-PCR H5 single-plex assay for reflex testing on the Hologic Panther Fusion Open Access platform.

Main Results:

  • All three evaluated commercial assays reliably detected H5N1 at low viral concentrations.
  • The developed real-time RT-PCR H5 assay demonstrated capability for H5 subtype differentiation.

Conclusions:

  • Current commercial assays, while detecting H5N1, do not differentiate the H5 subtype.
  • Integration of validated commercial assays with a targeted H5 assay enhances clinical decision-making and public health surveillance for H5N1.
  • Improved diagnostic strategies reduce the risk of missed H5N1 infection cases.

Related Concept Videos